Healthcare Industry News:  antibiotic 

Devices Wound Care

 News Release - May 28, 2013

ULURU Inc. Announces Publication On Altrazeal(R) In The International Journal Of Molecular Sciences

ADDISON, Texas, May 28, 2013 -- (Healthcare Sales & Marketing Network) -- ULURU Inc. (ULUR) today announced the publication, in the International Journal of Molecular Sciences, of an article, titled, "Bacterial Growth Kinetics Under a Novel Flexible Methacrylate Dressing Serving as a Drug Delivery Vehicle for Antiseptics."

The article describes the investigation of the antimicrobial efficacy and influence on bacterial growth kinetics in combination with three antiseptics in an in-vitro porcine wound model. The study demonstrated that a methacrylate dressing (Altrazeal®) applied into an experimental wound as a powder, which then transforms into a flexible, wound-contouring dressing, can be combined with a number of antiseptics and serve as a drug delivery system for antimicrobial compounds. Depending on the antiseptic chosen, bacterial load can be controlled up to 5 days (length of the study) and controlled non-antimicrobial or antimicrobial effect may be achieved using the same type of wound dressing.

Commenting on the publication, Kerry P. Gray, President and CEO of ULURU Inc., stated "This is an important publication for the Company in a peer reviewed journal. This opens new possibilities for topical antimicrobial treatment and prophylactic strategies in wound care management. Clinicians have experienced favorable clinical results using antimicrobials in combination with Altrazeal®. This could represent a major advancement in controlling microbial contaminants in acute and chronic wounds and avoid, in many cases, the use of antibiotics."

About ULURU Inc.

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at For further information about Altrazeal®, please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the use of antimicrobial dressings for the treatment of wounds. When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and other reports filed by us with the Securities and Exchange Commission.

Source: ULURU

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.